25Transition and Gaps in AYA Survivorship Care

preview_player
Показать описание
David Freyer, Children's Hospital Los Angeles
  1. NASEM Health and Medicine Division
  2. IOM
  3. Institute of Medicine
  4. NAS
  5. National Academies
  6. NRC
Рекомендации по теме
25Transition and Gaps 0:27:37

25Transition and Gaps in AYA Survivorship Care

Survival, Toxicity and 0:37:25

Survival, Toxicity and Survivorship in AYA Oncology

30Workshop Wrap Up 0:21:56

30Workshop Wrap Up

31Adjourn 0:01:58

31Adjourn

2Overview of the 0:03:57

2Overview of the Workshop

Dr. Harrison on 0:01:02

Dr. Harrison on Choosing Frontline Treatment for RCC

On Last Year's 0:17:39

On Last Year's Language | Dr. Helen Marshall | Near-Future Fictions

11/07/2019 - Session 0:04:12

11/07/2019 - Session 4: Intro

Symposium Session IV: 1:10:03

Symposium Session IV: Late Effects and Survivorship

02/12/2019 - Session 0:04:17

02/12/2019 - Session 6: Nevidjon

11/07/2019 - Session 0:02:42

11/07/2019 - Session 2: Intro

Healthbreak - Treatment 0:01:01

Healthbreak - Treatment for Peripheral Artery Disease, Hong Zheng, DO

02/11/2019 - Session 0:18:10

02/11/2019 - Session 1: Nevidjon

Changing treatment landscapes, 0:02:48

Changing treatment landscapes, new challenges for hemonc pharmacists

What is HOPA 0:07:36

What is HOPA doing for pharmacists and cancer patients

Utilization of HSCT 0:03:07

Utilization of HSCT globally for myeloma

4/27/2017 - Overview: 0:12:40

4/27/2017 - Overview: Meier, Nevidjon

MCP 60 Seconds 0:01:01

MCP 60 Seconds With Dr Ashwani Singal on Spontaneous Bacterial Peritonitis

HOPA 2018/19: what’s 0:03:16

HOPA 2018/19: what’s next?

Kidney Cancer Association 0:13:48

Kidney Cancer Association

4/27/2017 - Wrap-Up 0:03:09

4/27/2017 - Wrap-Up and Adjourn

Cancer Survivorship Care 0:52:07

Cancer Survivorship Care in Primary Care - H. Tackitt - 20220420

Dr Jeremy Whalen 0:01:39

Dr Jeremy Whalen Cites Patient Safety, Total Cost of Care as Key Policy Goals for Prime Therapeutics

The 2018 HOPA 0:03:01

The 2018 HOPA conference: targeting the future of oncology pharmacy